Skip to main content

MoneyWorks4Me

Wockhardt informs about press release

31 Jan 2025 Evaluate
Pursuant to Regulation 30 of Listing Regulations, Wockhardt has informed that it enclosed Press Release titled ‘Wockhardt’s Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves highest-ever efficacy meeting superiority in a global, pivotal, registration-enabling Phase III study in complicated urinary tract infection (cUTI) achieving 96.8% clinical cure rate’. A copy of the same will also be uploaded on the Company’s website www.wockhardt.com.

The above information is a part of company’s filings submitted to BSE.
Peers
Company Name CMP
Sun Pharma. Inds. 1880.90
Dr. Reddys Labs. 1377.00
Cipla 1393.00
Lupin 1980.00
Zydus Lifesciences 1191.00
View more..